ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes
This study will be conducted to determine the pharmacodynamics, cardiovascular and biochemical effects of succinylcholine when given during electroconvulsive therapy. (ECT). This is a single center, prospective, study in patients who will be receiving ECT as indicated and prescribed by their psychiatrist. The study will be performed twice on each patient, 48-72 hours apart during consecutively scheduled ECT procedures.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||The Muscle Biochemical, Serum Potassium and Cardiovascular Changes After Succinylcholine in Patients Undergoing Electroconvulsive Therapy.|
|Study Start Date:||October 2008|
Patients will receive the anesthetic that is traditionally given which includes appropriate doses of succinylcholine. Serum potassium and creatinine phosphokinase (CK) levels will be determined pre and post anesthesia; serum and urine myoglobin will be determined post anesthesia. Vital signs data [i.e., heart rate (arrhythmias) and arterial blood pressure] will be compared pre and post anesthesia. In addition patients will be asked about the presence of muscle pain (myalgia) 1 hour before discharge from the recovery room and the following day post ECT.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00750906
|United States, California|
|University of California San Francisco|
|San Francisco, California, United States, 94143|
|Study Director:||Ronald D Miller, MD||University of California, San Francisco|